ALLO
Allogene Therapeutics, Inc.
+0.04 (+2.37%)1.73USD2.0M成交股數598M市值–本益比(近四季)128.8股價營收比–營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 4.6M | – | 0.00 | 0.00 | 0.00-100% | 0.00-100% | 0.00-100% | 0.00-100% | 22K | 21K | 22K | 22K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 30.7M | 32.0M | 28.6M | 31.2M | 40.2M | 50.2M | 44.7M | 50.4M | 52.3M | 54.7M | 46.0M | 62.0M |
| 銷售管理費用 | 20.8M | 14.1M | 13.8M | 13.7M | 14.3M | 15.0M | 16.3M | 16.1M | 17.3M | 17.2M | 17.0M | 18.5M |
| 營業利益 | −46.9M-17% | −46.1M-29% | −42.4M-41% | −44.9M-37% | −56.8M-18% | −65.2M-23% | −71.8M+14% | −71.4M-11% | −69.5M | −85.1M | −63.0M | −80.5M |
| 營業利益率 | -1,011.2% | – | – | – | – | – | – | – | -315,927.3% | -405,281.0% | -286,345.5% | -366,090.9% |
| 稅後淨利 | −42.7M-16% | −42.6M-29% | −38.8M-41% | −41.4M-38% | −50.9M-22% | −59.7M-30% | −66.3M+6% | −66.4M-16% | −65.0M | −85.8M | −62.3M | −79.2M |
| 淨利率 | -919.8% | – | – | – | – | – | – | – | -295,454.5% | -408,466.7% | -283,122.7% | -360,145.5% |
| 稀釋 EPS | -0.13-43% | -0.18-36% | -0.17-47% | -0.19-46% | -0.23-39% | -0.28-43% | -0.32-14% | -0.35-35% | -0.38 | -0.49 | -0.37 | -0.54 |
| 稀釋股數 | 329M | 240M | 221M | 222M | 219M | 215M | 209M | 190M | 169M | 157M | 168M | 147M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 38.6M | 30.3M | 51.7M | 37.8M | 52.3M | 42.5M | 51.2M | 171M | 51.0M | 83.2M | 69.2M | 155M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 550M | 396M | 416M | 440M | 471M | 508M | 589M | 647M | 586M | 643M | 713M | 773M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 114M | 117M | 123M | 124M | 126M | 123M | 125M | 132M | 125M | 131M | 133M | 152M |
| 股東權益 | 436M | 279M | 293M | 315M | 345M | 385M | 464M | 515M | 461M | 512M | 581M | 621M |
| 負債比 | 20.7% | 29.6% | 29.7% | 28.3% | 26.8% | 24.1% | 21.3% | 20.4% | 21.3% | 20.3% | 18.6% | 19.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −12.9M-76% | – | – | – | −52.9M | – | – | −55.9M | – | – | – |
| 資本支出 | – | 9K | – | – | – | 99K | – | – | 8K | – | – | – |
| 自由現金流 | – | −12.9M-76% | – | – | – | −53.0M | – | – | −55.9M | – | – | – |
| 折舊攤銷 | – | 2.9M | – | – | – | 3.1M | – | – | 3.6M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -254,122.7% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 0.00 | -100.0% | −191M | –% | -0.87 | −150M |
| FY2024 | 22K | -76.8% | −258M | -1,170,863.6% | -1.32 | −201M |
| FY2023 | 95K | -39.1% | −327M | -344,489.5% | -2.09 | −239M |
| FY2022 | 156K | -99.9% | −340M | -218,214.1% | -2.38 | −226M |
| FY2021 | 114M | – | −182M | -159.6% | -1.34 | −206M |
| FY2020 | 0.00 | – | −316M | –% | -2.63 | −181M |
| FY2019 | 0.00 | – | −185M | –% | -1.83 | −188M |
| FY2019 | – | – | −243M | –% | – | – |